Ixabepilone injection
Products billed under this code include Ixempra Kit.
Payment limit per 1 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Ixempra Kit.
Payment limit per 1 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Ixempra Kit | R-Pharm US, LLC | 70020-1910-01 | 15 | $2,092.47 |
| Ixempra Kit | R-Pharm US, LLC | 70020-1911-01 | 45 | $6,277.41 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $139.498 | −$0.256 | 1 MG | Ixabepilone injection | v1, posted September 17, 2026 |
| 3Q26 | $139.754 | +$0.005 | 1 MG | Ixabepilone injection | v1, posted September 15, 2026 |
| 2Q26 | $139.749 | −$0.227 | 1 MG | Ixabepilone injection | v1, posted September 15, 2026 |
| 1Q26 | $139.976 | +$0.764 | 1 MG | Ixabepilone injection | v1, posted September 15, 2026 |
| 4Q25 | $139.212 | +$0.54 | 1 MG | Ixabepilone injection | v1, posted September 8, 2026 |
| 3Q25 | $138.672 | +$2.465 | 1 MG | Ixabepilone injection | v1, posted March 10, 2026 |
| 2Q25 | $136.207 | −$0.22 | 1 MG | Ixabepilone injection | v1, posted March 10, 2026 |
| 1Q25 | $136.427 | +$2.37 | 1 MG | Ixabepilone injection | v1, posted December 19, 2025 |
| 4Q24 | $134.057 | +$0.893 | 1 MG | Ixabepilone injection | v1, posted June 11, 2025 |
| 3Q24 | $133.164 | +$5.668 | 1 MG | Ixabepilone injection | v1, posted June 11, 2025 |
| 2Q24 | $127.496 | −$0.578 | 1 MG | Ixabepilone injection | v1, posted March 11, 2025 |
| 1Q24 | $128.074 | +$0.50 | 1 MG | Ixabepilone injection | v1, posted December 19, 2024 |
| 4Q23 | $127.574 | +$5.026 | 1 MG | Ixabepilone injection | v1, posted October 10, 2024 |
| 3Q23 | $122.548 | +$0.669 | 1 MG | Ixabepilone injection | v1, posted June 5, 2024 |
| 2Q23 | $121.879 | +$3.231 | 1 MG | Ixabepilone injection | v1, posted February 23, 2024 |
| 1Q23 | $118.648 | +$1.91 | 1 MG | Ixabepilone injection | v1, posted December 6, 2023 |
| 4Q22 | $116.738 | −$0.319 | 1 MG | Ixabepilone injection | v1, posted June 22, 2023 |
| 3Q22 | $117.057 | +$2.673 | 1 MG | Ixabepilone injection | v1, posted June 9, 2023 |
| 2Q22 | $114.384 | +$0.198 | 1 MG | Ixabepilone injection | v1, posted December 14, 2022 |
| 1Q22 | $114.186 | +$2.07 | 1 MG | Ixabepilone injection | v1, posted June 8, 2022 |
| 4Q21 | $112.116 | +$0.03 | 1 MG | Ixabepilone injection | v1, posted June 2, 2022 |
| 3Q21 | $112.086 | +$0.228 | 1 MG | Ixabepilone injection | v1, posted June 2, 2022 |
| 2Q21 | $111.858 | +$9.739 | 1 MG | Ixabepilone injection | v1, posted March 1, 2022 |
| 1Q21 | $102.119 | – | 1 MG | Ixabepilone injection | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.